Scientists Finally Crack an "Undruggable" Pancreatic Cancer Target
Pancreatic cancer has long been one of the most lethal cancers, with few effective treatment options available to patients. However, a new drug called daraxonrasib is offering renewed hope after successfully targeting the KRAS mutation that fuels the majority of pancreatic tumors—an approach many scientists once considered impossible.
In a major clinical trial, daraxonrasib demonstrated remarkable efficacy, nearly doubling survival for patients with advanced disease and reducing the risk of death by 60%. This breakthrough represents a significant milestone in oncology, particularly given the historical difficulty of treating pancreatic cancer and the longstanding perception of KRAS as an "undruggable" target.